| 2.57 Data as of Jun 18 |  +0.07 / +2.80%Today’s Change | 1.49 Today|||52-Week Range 4.70 | +56.71% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $54.5M |
Company Description
MediciNova, Inc. is a development stage company with interest in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The company's development pipeline consists of eight product development programs which have been in clinical development for the treatment of asthma, acute exacerbations of asthma, diabetic neuropathic pain, opioid addiction, multiple sclerosis, other CNS disorders, interstitial cystitis, or IC, solid tumor cancers, Generalized Anxiety Disorder/insomnia, preterm labor and urinary incontinence. MediciNova was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in San Diego, CA.
Employees
Shareholders
| Individual stakeholders | 14.61% |
| Other institutional | 1.87% |
| Mutual fund holders | 1.56% |
Top Executives
| Yuichi Iwaki, MD, PhD | President, Chief Executive Officer & Director |
| Michael J. Gennaro, MBA, CPA | Chief Financial & Accounting Officer |
| Kirk William Johnson, PhD | Chief Scientific Officer |
| Kazuko Matsuda, MD, PhD | Chief Medical Officer |
| Marie Lalas, MBA | Vice President & Controller |
.
